Loading...

KVUE - Kenvue Inc.

Analyst Coverage Resumed Signal for 03-01-2024
Analyst Coverage Resumed: KVUE rating Neutral by Goldman
Price Target: $20


Loading Chart KVUE

Stock Signal Information


Signal

Analyst Coverage Resumed: KVUE rating Neutral by Goldman
Price Target: $20
Report Date: 03-01-2024
Symbol: KVUE - Kenvue Inc.
Sector: Consumer Defensive
Industry: Household & Personal Products
Analyst Coverage Resumed: KVUE rating Neutral by Goldman
Price Target: $20

  KVUE Technical Analysis

Company Contact

Kenvue Inc. (KVUE)
199 Grandview Road
Skillman, NJ 08558
Phone: (732) 524-0400
Website: https://www.kenvue.com
CEO: Mr. Thibaut Mongon

KVUE, Kenvue Inc.

KVUE Kenvue Inc. Logo Image

NYSE, New York Stock Exchange


Company Profile

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.